The use of ultralow doses of antibodies to C-terminal fragment of angiotensin II AT1 receptor (kardos) in the therapy of arterial hypertension.

Abstract

Kardos monotherapy allows attaining the target levels of systolic and diastolic blood pressure in patients with high-risk and very-high-risk hypertension. We demonstrated excellent tolerability of the preparation in combination with reliable blood pressure decrease over 24 h, during day and night hours.

• Authors: V I Petrov, S V Nedogoda, O I Epshtein, T A Chalyabi, U A Brel', N G Chepurina, G V Mazina, M V Kachanova, L V Sabanov, S A Tarasov, Yu A Zabolotneva, A E Kolosova, S A Sergeeva
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 148 Issue 2 Pg. 332-4 (Aug 2009) ISSN: 1573-8221 [Electronic] United States
• PMID: 20027362 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antibodies
• Antihypertensive Agents
• Receptors, Angiotensin

Topics

• Adolescent
• Adult
• Aged
• Antibodies (administration & dosage, immunology, pharmacology, therapeutic use)
• Antihypertensive Agents (administration & dosage, immunology, pharmacology, therapeutic use)
• Blood Pressure (drug effects)
• Female
• Humans
• Hypertension (drug therapy)
• Male
• Middle Aged
• Receptors, Angiotensin (chemistry, immunology)
• Treatment Outcome
• Young Adult